STAT

Social connections first, science second: How biotech’s recipe for success has its limits

The pivotal financial decisions that determine which biotech companies will survive and which will fail are determined largely by social capital — not by science.

When Laura Indolfi set out to launch a biotech in Boston, she had an idea — and little else. She had never run a company before. She had no practical experience in fundraising.

But she was undeterred. In 2014 she founded PanTher Therapeutics, with the goal of turning a postdoctoral side project into a bona-fide drug delivery company.

“I took a leap of faith,” she told STAT.

Through her five-year odyssey, Indolfi learned a fundamental lesson about the biotech world: who you know can be as important — or even more important — as what you want to do.

First, her “leap of faith’’ needed to be backed up with data. But soon, she needed to match it with cold, hard cash. She met with as many venture capitalists as she could fit into her schedule, hoping to find a

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Pharmalittle: We’re Reading About An Amgen Obesity Drug, A Senate Bill On Shortages, And More
Amgen will no longer develop an early-stage obesity pill, and will instead focus on a more advanced injectable candidate to compete with Wegovy and Zepbound.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About AstraZeneca CEO Pay, Alternatives To WuXi And More
And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans.…
STAT2 min read
STAT+: Pharmalittle: We’re Reading About FTC Fighting ‘Junk’ Patents, Pfizer Direct-to-consumer Plans, And More
The FTC expanded its campaign against pharmaceutical companies for filing what it calls “junk” patent listings for 20 different brand-name treatments.

Related Books & Audiobooks